Skip to content

Clinical trials

Dyspnea trials in France

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Dyspnea Country / region: France Clear all

119 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20041
20061
20071
20081
20092
20103
20115
20122
20135
20145
20154
20168
20174
20186
20199
202017
20215
20224
202312
20244
202510
20269

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed70
Unknown status16
Recruiting14
Not yet recruiting9
Terminated8
Active, not recruiting1
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Assistance Publique - Hôpitaux de Paris24
Association pour le Développement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil9
University Hospital, Brest7
Hospices Civils de Lyon5
University Hospital, Toulouse5
University Hospital, Lille4
University Hospital, Montpellier4
Central Hospital, Nancy, France3
Centre Hospitalier Universitaire, Amiens3
Novartis Pharmaceuticals3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Dyspnea119
Pulmonary Disease, Chronic Obstructive18
Emergencies12
COVID-199
Asthma7
Heart Failure7
Lung Diseases6
Pulmonary Embolism5
Anxiety Disorders4
Respiratory Insufficiency4

Trials

Showing 26 to 50 of 119. Each trial links to its page on Pharma Observatory.

19 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.